1. Select Topics in Cardiovascular Medicine

2. Agenda

3. Cardiovascular Disease in Latin America

4. Prevalence Rates of CV Risk Factors: Results From Several Studies in Latin Americans

5. CV Mortality in Latin America

6. CV Risk Factor Reduction: Combination Therapy vs Placebo

7. Baseline Factors Associated With 4-Year Outcomes in Latin American Patients of the REACH Registry

8. Summary and Conclusions

9. An Integral Approach to Hypertension

10. ESH/ESC/JNC8 BP Treatment Recommendations

11. Results From the SPRINT Trial: SBP > 130? > 120?

12. Controversy Surrounding BP Measurement in SPRINT

13. Masked and NTH in the ARTS-DN ABPM Substudy With Finerenone

14. Treating Prehypertension to Reduce Incidence of CV Disease/Events

15. Summary and Conclusions

16. New Insights Into Dyslipidemia Therapy: Controlling Lipids to Reduce CV Risk

17. Changes in CV Mortality in Selected Regions, 1990-2013

18. Intervention Strategies Based on CV Risk Factors and Cholesterol Levels

19. Targets and Strategies for Cholesterol Reduction: Moving Beyond Statins

20. PCSK9 Inhibitors for Dyslipidemia: Results of the FOURIER Study

21. Summary and Conclusions

22. Heart Failure: How Can We Improve Timely Diagnosis and Effective Treatment?

23. Death Rates for Patients Hospitalized With HF: Europe and Latin America

24. Common Comorbidities Associated With HF

25. HF: Diagnostic Algorithm

26. Primary Endpoint Results: CANTOS

27. Effects of FCM on Hospitalizations and Mortality Rates: A Meta-Analysis

28. Summary and Conclusions

29. Future Strategies for the Prevention of CVD in Latin America

30. Introduction and Overview

31. COMPASS: Rivaroxaban With or Without Aspirin in Stable CVD

32. Cumulative Incidence of the Primary Outcome (CV Death, Stroke, or MI)

33. COMPASS Subgroup Analysis: PAD

34. COMPASS Results: Net Clinical Benefit

35. CANTOS Trial: Study Design

36. CANTOS Trial: Primary Endpoint Results

37. CANTOS Trial: Selected AEs

38. New Treatments and Cost/Benefit Considerations in Latin America

39. Selected Risk Factors: Results From the INTERHEART Latin America Study

40. Summary and Conclusions

41. Select Topics in Cardiovascular Medicine

42. Summary and Conclusions (1 of 2)

43. Summary and Conclusions (2 of 2)

44. Abbreviations

45. Abbreviations (cont)

46. Abbreviations (cont)

47. Abbreviations (cont)